

# PATENT COOPERATION TREATY

Re. EPO 03 DEC 2004

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

To:

Keller, Günter  
KELLER, Günter  
Lederer & Keller  
Prinzregentenstrasse 16  
80538 München  
ALLEMAGNE

LEDERER & KELLER  
15.09.2004

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing  
(day/month/year)

14.09.2004

Applicant's or agent's file reference  
02012302.2

## IMPORTANT NOTIFICATION

International application No.  
PCT/EP 03/05780

International filing date (day/month/year)  
03.06.2003

Priority date (day/month/year)  
04.06.2002

Applicant

BIOMAY PRODUKTIONS- UND HANDELS-AKTIENGESELLSCHAFT

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international  
preliminary examining authority:



European Patent Office - P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk - Pays Bas  
Tel. +31 70 340 - 2040 Tx: 31 651 epo nl  
Fax: +31 70 340 - 3016

Authorized Officer

Humbert, C

Tel. +31 70 340-4129




# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 02012302.2	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/EP 03/05780	International filing date (day/month/year) 03.06.2003	Priority date (day/month/year) 04.06.2002
International Patent Classification (IPC) or both national classification and IPC C12N15/29		
Applicant BIOMAY PRODUKTIONS- UND HANDELS-AKTIENGESELLSCHAFT		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 3 sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the opinion</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>		
Date of submission of the demand  17.11.2003	Date of completion of this report  14.09.2004	
Name and mailing address of the international preliminary examining authority:   European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized Officer  Bucka, A  Telephone No. +31 70 340-2279	



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/EP 03/05780**

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, Pages**

1-28 as originally filed

**Sequence listings part of the description, Pages**

1-5 as originally filed

**Claims, Numbers**

1-18 received on 27.08.2004 with letter of 27.08.2004

**Drawings, Sheets**

1/10-10/10 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.  
☒ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority in written form.  
☐ furnished subsequently to this Authority in computer readable form.  
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/EP 03/05780**

---

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	1-18
	No: Claims	
Inventive step (IS)	Yes: Claims	
	No: Claims	1-18
Industrial applicability (IA)	Yes: Claims	1-18
	No: Claims	

2. Citations and explanations

**see separate sheet**

**Re Item V**

**Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

- 1 The following documents (D) are considered to be relevant to this application:
  - D1: WO 96 13589 A (IMMULOGIC PHARMA CORP) 9 May 1996
  - D2: WO 94 01560 A (IMMULOGIC PHARMA CORP ;BOND JULIAN F (US); KUO MEI CHANG (US); POL) 20 January 1994
  - D3: FERREIRA FATIMA ET AL: 'Isolation and characterization of cDNA clones coding for mugwort (*Artemisia vulgaris*) pollen allergens.' INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. **124**, no. 1-3, January 2001, pages 77-79.
  - D4: HIRSCHWEHR R ET AL: 'ALLERGENS, IGE, MEDIATORS, INFLAMMATORY MECHANISMS. IDENTIFICATION OF COMMON ALLERGENIC STRUCTURES IN MUGWORT AND RAGWEED POLLEN' JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. **101**, no. 2, February 1998, pages 196-206.
- 2 The amendments of the claims submitted with letter of 27 August 2004 appear to be allowable in view of Article 34(2)(b) PCT.
- 3 The subject-matter of **claims 1 to 18** is new and therefore meets the requirements of Article 33(2) PCT.
- 4 The subject-matter of **claims 1 to 18** lacks inventiveness in the meaning of Article 33(3) PCT.

Claim 1 relates to an allergen from mugwort having the sequence as shown in SEQ ID NO: 1, which shows homology to an allergen from ragweed.

D3, which is considered to represent the closest prior art, describes the identification of several cDNAs encoding mugwort pollen allergens, from which the subject-matter of claim 1 differs in that the primary sequence of the antigen is different from those contained in the prior art.

The problem to be solved by the present invention therefore is considered to be the provision of a further or alternative mugwort pollen allergen.

The application provides the protein having the sequence SEQ ID NO: 1, thereby solving the problem.

D3 is referring to the same technical problem, namely the identification of mugwort antigens. In view of the teachings of D4, describing *inter alia* the cross-reactivity of antisera against ragweed allergens with allergens from mugwort, and in view of the availability of the cDNA expression library described in D3, the identification of the provided cDNA would have been straightforward to a person skilled in the art. D4 describes the cross-reactivity both of IgE antibodies and of rabbit antisera against the antigen profilin (figures 3 to 5). Therefore, the skilled person would have a reasonable expectation to succeed in the identification of related antigens from a different species, since the cross-reactivity of antibodies has been demonstrated in D4. D4 even teaches two approaches, which lead to the isolation of related antigens. Therefore, even if it would require much work, i. e. the use of both approaches, the skilled person would have the reasonable expectation to succeed in the identification of further, related antigens from mugwort. It is common to both approaches that the crossreactivity of antibodies is used to identify antigens from two different, related species. This is exactly the reasoning used in the application at issue for the isolation of a cDNA encoding a mugwort allergen.

The Applicant states that difficulties were encountered in the cloning of the antigen that required inventive activity to be overcome, and also that the skilled person "can in no way simply receive the specific sera required for the identification of a new antigen". However, the application does not describe any such cloning difficulties that would have required inventiveness to be overcome. Even more strikingly, the antisera used in the identification of the new antigen, was, according to the application, simply obtained from Dr. P. King. The antiserum in question was a rabbit antiserum (IgG) highly specific for *ragweed* pollen (page 15).

Therefore, the skilled artisan can expect to perform the cloning and expression of the corresponding cDNA in a fairly uncomplicated manner, even if this would require much work.

For the reasons outlined above, the solution proposed in **claims 1 to 18** cannot be considered as involving an inventive step (Article 33(3) PCT).